Datasets:
hackint0sh
/
Text-Clinical-Records

Dataset card Data Studio Files Community
text
stringlengths
0
197k
* Does A Subtle energy transmission and Tao Calligraphy Mindfulness increase Telomere Length in Peripheral Blood Leukocytes in adults?
* Will this increase of Telomere Length in Peripheral Blood Leukocytes in adults be statistically significant? Researchers will compare the length of Telomere in peripheral blood Leukocytes at beginning of the mindfulness practices to the length of Telomere in peripheral blood Leukocytes at 3 months and at 9 months of regular daily practices.
Participants will:
* Receive a transmission of Subtle energy at beginning of practices
* Visit the Laboratory for a blood sample taken at beginning, at 3 months and at 9 months of practices.
* Fill the Study Questionnaires at beginning, at 3 months and at 9 months of practices.
* Practice the Mindfulness with Tao Calligraphy daily 1 hour in the morning and 1 hour in the evening. conditions: Telomere Length conditions: Quality of Life studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The study will be performed as a Pilot follow-up study, should the 0 Hypothesis be successfully rejected, this study will be followed by a formal Double Blind Randomized Crossover Study.
We plan subjects may enter the study as a group and will have measurements done within short time frame from each other at beginning and at the end of 3 and 9 months.
As this is a pilot study, there will be no randomization into treatment and control group, as a control we will use the "Normal" values of telomere from general population. All subjects will receive a transmission and then will be practicing Tao Calligraphy mindfulness daily during the 9 months.
Every subject who is accepted into the study, will have blood sample taken for analysis and will fill Rand SF 36 Questionnaire. Afterwards, will receive transmission of subtle energy by Zhi Gang Sha (or his designee) and will be instructed on how to practice mindfulness with Tao Calligraphy. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 12 type: ACTUAL name: Mindfulness practice with Calligraphy measure: Telomere Length in Peripheral blood leukocytes measure: Quality of Life by John Ware's SF-36 Quality of Life questionnaire (that produces eight scores with 0-to-100 scale, 100 being the best possible outcome). sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sha Research Foundation (Branch) city: North Vancouver state: British Columbia zip: V7R 1P5 country: Canada lat: 49.31636 lon: -123.06934 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-04-10 uploadDate: 2024-03-28T15:14 filename: Prot_SAP_000.pdf size: 428331 hasResults: False
<|newrecord|> nctId: NCT06357650 id: CSQ-2024-001 briefTitle: Collaborative Open Research Initiative Study (CORIS-1) acronym: CORIS-1 overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-12-31 date: 2025-06-30 date: 2024-04-10 date: 2024-04-10 name: Chisquares Incorporated class: INDUSTRY briefSummary: The Collaborative Open Research Initiative Study (CORIS) is a groundbreaking international research endeavor aimed at exploring vital topics within the field of health professions education. At its core, CORIS embodies the spirit of inclusivity by opening its doors to contributors from all corners of the globe, putting the power of research into the hands of the global community and fostering an environment of open collaboration and meaningful contribution. We invite anyone and everyone to join as collaborators and suggest questions for inclusion in the survey, ensuring that the research process is enriched by diverse perspectives. As a collaborator, you will not only have the opportunity to actively engage in survey design, question formulation, and the entire research process from start to finish, but also gain the prospect of achieving valuable publications, which may boost your professional career. conditions: Patient Engagement conditions: COVID-19 conditions: Preventable Disease, Vaccine conditions: Burnout, Professional conditions: Emerging Infectious Disease conditions: Artificial Intelligence conditions: Climate Change conditions: Online Education conditions: Mental Health Issue conditions: Substance Use Disorders studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 15000 type: ESTIMATED name: No intervention. This is an observational study measure: Percentage of health professions schools implementing changes in patient care strategies before versus after the COVID-19 pandemic. measure: Percentage of personnel in health professions education with adequate epidemic preparedness and readiness. measure: Percentage of faculty and staff in health professions schools experiencing burnout. measure: Percentage of healthcare professionals who report the integration and utilization of artificial intelligence (AI) in their education and practice. measure: Percentage of participants expressing positive attitudes and perceptions towards climate change and the role of individuals and society in mitigating it. measure: Percentage of participants reporting effectiveness and challenges of remote learning and online education in health professions schools. measure: Percentage of personnel within health professions education reporting substance use behaviors and their implications. sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<|newrecord|> nctId: NCT06357637 id: 59/2023 briefTitle: Abdominal Circumference Measure in Caesarian Section acronym: ACirCuS overallStatus: RECRUITING date: 2023-12-01 date: 2024-05-01 date: 2024-05-31 date: 2024-04-10 date: 2024-04-10 name: CHU Mohammed VI Marrakech class: OTHER briefSummary: The goal of this observational study is to evaluate preoperative measures of abdominal circumference in patients admitted for a cesarean section. The main questions it aims to answer are:
* Can preoperative abdominal circumference predict patients with difficult spinal anesthesia
* Can preoperative abdominal circumference predict the occurrence of maternal hypotension during cesarean section Participants will be examined preoperatively in terms of visibility and palpation of spinous processes, abdominal circumference will be measured in the supine and sitting positions with other clinical parameters. Spinal anesthesia will be performed by the same experienced anesthesiologist with a standardized procedure. The number of skin punctures, needle reorientations, traumatic Cerebrospinal fluid, need for a paramedian approach or failure will be recorded. Maternal blood pressure and vasopressor requirements will also be monitored. conditions: Anesthesia, Spinal conditions: Cesarean Section studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Measure of abdominal circumference measure: Number of patients with difficult spinal anesthesia measure: Rate of Maternal hypotension sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU Mohammed VI status: RECRUITING city: Marrakech zip: 40000 country: Morocco name: MERYEM ESSAFTI, MD role: CONTACT phone: +212662393700 email: [email protected] name: MARINA BOKOBA, MD role: CONTACT phone: +242065166209 email: [email protected] name: MERYEM ESSAFTI, MD role: PRINCIPAL_INVESTIGATOR name: MARINA NDE BOKOBA, MD role: SUB_INVESTIGATOR lat: 31.63416 lon: -7.99994 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2024-01-10 uploadDate: 2024-01-23T03:56 filename: Prot_000.pdf size: 162775 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-04-01 uploadDate: 2024-04-06T11:11 filename: ICF_001.pdf size: 350456 hasResults: False
<|newrecord|> nctId: NCT06357624 id: Physiotherapy briefTitle: Effectiveness of Mulligan Mobilization Technique overallStatus: COMPLETED date: 2023-01-01 date: 2023-05-30 date: 2023-05-30 date: 2024-04-10 date: 2024-04-10 name: Karabuk University class: OTHER briefSummary: The aim of this study was to investigate the effects of the Mulligan mobilization technique (MMT) on pain intensity, joint position sense (JPS), kinesiophobia, and disability level in individuals with nonspecific neck pain. A total of 34 female individuals with nonspecific neck pain were included in the study. Pain intensity, JPS, kinesiophobia, and disability levels of all participants were evaluated before and after the 3-week intervention. Participants were randomly divided into two groups. In the first group, the participants received MMT by the physiotherapist twice a week for 3 weeks, and self-mobilization techniques as a home exercise program. The second group was trained only self-mobilization techniques. conditions: Neck Pain conditions: Disability Physical conditions: Kinesiophobia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 34 type: ACTUAL name: Mulligan mobilization name: Self-Mobilization measure: Disability measure: Neck Pain Severity measure: Joint Position Sense sex: FEMALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tarik Ozmen city: Karabük country: Turkey lat: 41.20488 lon: 32.62768 hasResults: False
<|newrecord|> nctId: NCT06357611 id: OST1_015 briefTitle: Combination of Two Osteopathic Techniques for the Hamstring's Stretching Capacity in Basketball Female Players overallStatus: RECRUITING date: 2024-09-16 date: 2024-12-01 date: 2024-12-17 date: 2024-04-10 date: 2024-04-10 name: Natália Maria Oliveira Campelo class: OTHER briefSummary: It is known that there are studies that prove the effectiveness of muscle energy techniques and the fourth ventricle technique separately, however, information is scarce regarding the combination of the two and their effectiveness in the population. The aim of this randomized controlled study is to compare the immediate effects of the techniques compared to the muscle energy technique alone in female basketball players. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: In order to allocate each participant to an intervention group, each voluntary participation questionnaire was assigned a number. Subsequently, all the numbers of the participants in the sample were randomly distributed among the 3 groups by the principal investigator. primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 30 type: ESTIMATED name: Simulated technique name: Muscle energy technique name: 4th ventricle technique and muscular energy technique measure: Altered range of motion of the hamstring muscles. sex: FEMALE minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: Escola Superior de Saúde do Porto status: RECRUITING city: Porto zip: 4200-072 country: Portugal name: Natália Campelo role: CONTACT phone: +35122 206 1000 email: [email protected] name: Natália MO Campelo role: PRINCIPAL_INVESTIGATOR lat: 41.14961 lon: -8.61099 hasResults: False
<|newrecord|> nctId: NCT06357598 id: QYFYEC2023-95 briefTitle: Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer acronym: PILOT overallStatus: RECRUITING date: 2024-01-18 date: 2024-12-31 date: 2025-12-31 date: 2024-04-10 date: 2024-04-10 name: The Affiliated Hospital of Qingdao University class: OTHER briefSummary: Explorative study, which evaluates the effect of Tislelizumab combined with chemotherapy in neoadjuvant treatment of stage Ⅲ unresectable non-small-cell lung carcinoma. conditions: Non-small-cell Lung Cancer (NSCLC) studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Tislelizumab name: Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC) name: Carboplatin or Cisplatin name: Surgery measure: R0 Resection Rate measure: Objective Response Rate (ORR) measure: Resectability Rate measure: Major Pathological Response (MPR) Rate measure: Rate of grade 3 and higher grade treatment-related adverse events measure: Progression-Free Survival (PFS) measure: Pathological Complete Response (pCR) Rate sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: the Affiliated Hospital of Qingdao University status: RECRUITING city: Qingdao state: Shandong zip: 266000 country: China name: Zhe Wu, PhD role: CONTACT phone: +86 17863934867 email: [email protected] lat: 36.06488 lon: 120.38042 hasResults: False
<|newrecord|> nctId: NCT06357585 id: SBUBURCUCALİK briefTitle: Providing Web-based Training to Parents Of Children With Leukemia overallStatus: RECRUITING date: 2021-09-24 date: 2024-04 date: 2024-04 date: 2024-04-10 date: 2024-04-10 name: Saglik Bilimleri Universitesi class: OTHER briefSummary: Following and implementing innovations and current developments in care practices for children diagnosed with leukemia and their parents will allow the quality of care to increase. The purpose of this research is to evaluate the effect of web-based education given to parents of children diagnosed with leukemia on their knowledge level, satisfaction and self-efficacy.
The research is a single-blind randomized controlled experimental research type. The research will be conducted in a single center, Ankara Bilkent City Hospital MH4 Children's Hospital Hematology-Oncology Clinics and Leukemia Polyclinic. The population of the research consists of parents of children diagnosed with leukemia between the ages of 2-18 who are followed and treated in the specified places. The sample of the research consists of 72 participants, 36 in the experimental group (the group that received web-supported training) and 36 in the control group (the group that continued routine treatment).
The consent of the parents who meet the research criteria and voluntarily agree to participate in the study will be obtained with the "Informed Voluntary Consent Form" and the parents in both the experimental group and the control group will be given the "Child and Parent Introductory Information Form", "Child with Leukemia Parent Information Level Pre-Test Evaluation Form". ", "Generalized Perceived Self-Efficacy Scale" will be applied. Once the sufficient number is reached, web-based training will be provided to the parents in the experimental group. "Parents of Children with Leukemia Knowledge Level Post-Test Evaluation Form", "Generalized Perceived Self-Efficacy Scale" and "Web-Based Parents of Children with Leukemia Training Satisfaction Evaluation Form" will be applied to the parents who complete the training. No intervention will be made to the parents in the control group, and the children will continue their routine care and treatment process. The "Child with Leukemia Parent Knowledge Level Posttest Evaluation Form" and the "Generalized Perceived Self-Efficacy Scale" will also be applied to the parents in the control group. conditions: Leukemia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Web-based training will be provided to parents in the experimental group, and parents in the control group will continue their routine treatment and care process. primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: Participant blinding was done because the parents who participated in the study voluntarily did not know which group they were in until the end of the study. whoMasked: PARTICIPANT count: 72 type: ESTIMATED name: Web based education name: inactive group measure: Child with Leukemia Parent Knowledge Level Pre-Test Evaluation Form measure: Child with Leukemia Parent Knowledge Level Post-Test Evaluation Form measure: Web-Based Child with Leukemia Parent Education Satisfaction Evaluation Form measure: Generalized Perceived Self-Efficacy Scale measure: Generalized Perceived Self-Efficacy Scale sex: ALL minimumAge: 2 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: University of Health Sciences status: RECRUITING city: Ankara state: Keçiören zip: 06018 country: Turkey name: Burcu ÇALIK BAĞRIYANIK role: CONTACT phone: 05067075349 email: [email protected] lat: 39.91987 lon: 32.85427 hasResults: False
<|newrecord|> nctId: NCT06357572 id: ENZ13-2024 briefTitle: Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem overallStatus: COMPLETED date: 2024-03-26 date: 2024-03-27 date: 2024-03-27 date: 2024-04-10 date: 2024-04-10 name: Enzyre B.V. class: INDUSTRY name: Instytut Hematologii i Transfuzjologii, Warschau, Poland briefSummary: The goal of this observational study is to assess if the version A of the HemA EnzySystem, a novel portable coagulation testing platform, can be used in patients with hemophilia A treated with Factor VIII Bypassing Agent (FEIBA). The main question\[s\] it aims to answer are:
* Can the version A of the HemA EnzySystem can record thrombin generation within a time frame of 60 min in fresh whole blood samples of patients with hemophilia A treated with FEIBA?
* Are the TGA results of the version A of the HemA EnzySystem in agreement with the TGA results obtained with conventional methods in fresh non frozen plasma?
Participants are asked to fill in a questionnaire regarding their general health and hemophilia treatment. Subsequently, blood will be drawn from the patients before, and at 30, 120, and 240 minutes after FEIBA administration. Whole blood is immediately tested using the Version A HemA EnzySystem, and plasma is generated for testing with the Ceveron s100 (Technoclone). Leftover samples are frozen for later additional coagulation testing. conditions: Hemophilia A With Inhibitor conditions: Hemophilia A studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 6 type: ACTUAL name: Thrombin generation assay (EnzySystem HemA version A - whole blood) name: Thrombin generation assay (Ceveron s100 (Technoclone) - fresh plasma) name: Additional coagulation tests measure: Time between venipuncture and TGA result measure: Agreement between TGA obtained with the EnzySystem HemA version A and conventional TGA results sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Institute of Hematology and Blood Transfusion city: Warsaw state: Mazowieckie Województwo country: Poland lat: 52.22977 lon: 21.01178 hasResults: False
<|newrecord|> nctId: NCT06357559 id: OCTA in Myopic CNV briefTitle: OCTA Changes in Choroidal Neovascularization in High Myopia overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2024-09-15 date: 2024-12-01 date: 2024-04-10 date: 2024-04-10 name: Sohag University class: OTHER briefSummary: To Analyze the Ability of Optical Coherence Tomography Angiography ( OCT-A ) to detect the presence of myopic Choroidal Neovascularization and to describe the structural features of Myopic CNV.. conditions: Myopic Choroidal Neovascularisation studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 100 type: ESTIMATED name: OCTA measure: Describing the Choroidal Neovascularization in High Myopic Patients diagnosed by OCTA sex: ALL minimumAge: 10 Years maximumAge: 75 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<|newrecord|> nctId: NCT06357546 id: RECHMPL23_0411 id: 2023-A02424-41 type: OTHER domain: N° ID-RCB briefTitle: Evaluation of the Absence of Intraoperative Bladder Catheterization in Case of Planned Cesarean Section acronym: C2S overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-07-01 date: 2024-09-01 date: 2024-04-10 date: 2024-04-10 name: University Hospital, Montpellier class: OTHER briefSummary: The hypothesis of this trial is that the absence of systematic bladder catheterization in patients performing spontaneous urination in the hour preceding the planned cesarean section under spinal anesthesia would not lead to more bladder heterocatheterization for postpartum urinary retention (RUPP) in the 24 hours post-cesarean section than systematic intraoperative bladder catheterization up to 2 hours post-surgery. conditions: Pregnant Women conditions: Cesarean Section studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A randomization list by blocks of random size and stratified by center, by scarred uterus (with or without scar) and Body Mass Index (BMI) at the start of pregnancy (\<30 and ≥30), will be established by a methodologist independent of the study. Patients will be randomized into each group at a ratio of 1:1. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The care provider carrying out the heterocatheterization will be blinded to the participant's randomization group. whoMasked: CARE_PROVIDER count: 500 type: ESTIMATED name: Spontaneous urination during the hour before caesarean section. name: Systematic bladder catherization during caesarean section. measure: Necessity of heterocatheterization within 24 hours following the cesarean section. measure: Experience of childbirth measure: Duration of preoperative preparation measure: Operating time measure: Duration of post-operative hospitalization measure: Time to resume ambulation measure: First urination measure: Pain during the first urination or the first heterocatheterization measure: Discomfort during the first urination or the first heterocatheterization measure: Additional prescription for painkillers measure: Urinary infection detection measure: Occurrence of surgical difficulties measure: Occurrence of operative complications measure: Amount of bleeding measure: Presence of symptoms suggestive of a urinary infection measure: Presence of functional signs (dysuria, incontinence, delayed bleeding or others) measure: Time before resuming spontaneous urination sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Montpellier University Hospital city: Montpellier zip: 34295 country: France name: Martha DURAES, MD role: CONTACT phone: +334.67.33.65.32 email: [email protected] name: Martha DURAES, MD role: PRINCIPAL_INVESTIGATOR name: Florent FUCHS, MD PhD role: SUB_INVESTIGATOR lat: 43.61092 lon: 3.87723 facility: Nîmes University Hospital city: Nîmes zip: 30029 country: France name: Audrey LAMOUROUX, MD role: CONTACT email: [email protected] name: Audrey LAMOUROUX, MD role: PRINCIPAL_INVESTIGATOR name: Vincent LETOUZEY, MD PhD role: SUB_INVESTIGATOR lat: 43.83333 lon: 4.35 hasResults: False
<|newrecord|> nctId: NCT06357533 id: D7632C00001 briefTitle: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations acronym: TROPION-Lung10 overallStatus: NOT_YET_RECRUITING date: 2024-04-26 date: 2030-05-24 date: 2030-05-24 date: 2024-04-10 date: 2024-04-10 name: AstraZeneca class: INDUSTRY name: Daiichi Sankyo briefSummary: The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations. conditions: Non-Small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel Assignment primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Open-label, sponsor-blinded whoMasked: OUTCOMES_ASSESSOR count: 675 type: ESTIMATED name: Datopotamab Deruxtecan name: Rilvegostomig name: Pembrolizumab measure: Progression-Free Survival (PFS) in TROP2 biomarker positive participants. measure: Overall Survival (OS) in TROP2 biomarker positive participants. measure: Progression-Free Survival (PFS) in the intent-to-treat (ITT) population. measure: Overall Survival (OS) in the intent-to-treat (ITT) population. measure: Objective Response Rate (ORR) measure: Duration of Response (DoR) measure: Participant-reported lung cancer symptoms of NSCLC in participants treated with Dato-DXd in combination with rilvegostomig relative to pembrolizumab. measure: Participant-reported physical functioning in participants treated with Dato DXd in combination with rilvegostomig relative to pembrolizumab. measure: Participant-reported GHS/QoL in participants treated with Dato-DXd in combination with rilvegostomig relative to pembrolizumab. measure: Pharmacokinetics (PK) measure: Immunogenicity measure: Second Progression-Free Survival (PFS2). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Research Site city: Clayton zip: 3168 country: Australia lat: -37.91667 lon: 145.11667 facility: Research Site city: Melbourne zip: 3000 country: Australia lat: -37.814 lon: 144.96332 facility: Research Site city: South Brisbane zip: QL 4101 country: Australia lat: -27.48034 lon: 153.02049 facility: Research Site city: Innsbruck zip: 6020 country: Austria lat: 47.26266 lon: 11.39454 facility: Research Site city: Krems zip: 3500 country: Austria lat: 48.40921 lon: 15.61415 facility: Research Site city: Linz zip: 4020 country: Austria lat: 48.30639 lon: 14.28611 facility: Research Site city: Rankweil zip: 6830 country: Austria lat: 47.27108 lon: 9.64308 facility: Research Site city: Wien zip: 1140 country: Austria lat: 48.20849 lon: 16.37208 facility: Research Site city: Wien zip: 1210 country: Austria lat: 48.20849 lon: 16.37208 facility: Research Site city: Rio de Janeiro zip: 22211-230 country: Brazil lat: -22.90278 lon: -43.2075 facility: Research Site city: Vancouver state: British Columbia zip: VSZ 4E6 country: Canada lat: 49.24966 lon: -123.11934 facility: Research Site city: Winnipeg state: Manitoba zip: R3E 0V9 country: Canada lat: 49.8844 lon: -97.14704 facility: Research Site city: London state: Ontario zip: N6A 4L6 country: Canada lat: 42.98339 lon: -81.23304 facility: Research Site city: Newmarket state: Ontario zip: L3Y 2P9 country: Canada lat: 44.05011 lon: -79.46631 facility: Research Site city: Oshawa state: Ontario zip: L1G 2B9 country: Canada lat: 43.90012 lon: -78.84957 facility: Research Site city: Toronto state: Ontario zip: M4N 3M5 country: Canada lat: 43.70011 lon: -79.4163 facility: Research Site city: Lévis state: Quebec zip: G6V 0B8 country: Canada lat: 46.80326 lon: -71.17793 facility: Research Site city: Montreal state: Quebec zip: H3T 1E2 country: Canada lat: 45.50884 lon: -73.58781 facility: Research Site city: Montreal state: Quebec zip: H4J 1C5 country: Canada lat: 45.50884 lon: -73.58781 facility: Research Site city: Rimouski state: Quebec zip: G5L 5T1 country: Canada lat: 48.44879 lon: -68.52396 facility: Research Site city: Trois-Rivieres state: Quebec zip: G8Z 3R9 country: Canada lat: 46.34515 lon: -72.5477 facility: Research Site city: Chicoutimi zip: G7H 5H6 country: Canada lat: 48.41963 lon: -71.06369 facility: Research Site city: Gauting zip: 82131 country: Germany lat: 48.06919 lon: 11.37703 facility: Research Site city: Budapest zip: 1121 country: Hungary lat: 47.49801 lon: 19.03991 facility: Research Site city: Gyula zip: 5700 country: Hungary lat: 46.65 lon: 21.28333 facility: Research Site city: Győr zip: 9024 country: Hungary lat: 47.68333 lon: 17.63512 facility: Research Site city: Kecskemét zip: 6000 country: Hungary lat: 46.90618 lon: 19.69128 facility: Research Site city: Salgótarján zip: 3100 country: Hungary lat: 48.09872 lon: 19.80303 facility: Research Site city: Szekszárd zip: 7100 country: Hungary lat: 46.35014 lon: 18.70905 facility: Research Site city: Székesfehérvár zip: 8000 country: Hungary lat: 47.18995 lon: 18.41034 facility: Research Site city: Törökbálint zip: 2045 country: Hungary lat: 47.42931 lon: 18.91356 facility: Research Site city: Bergamo zip: 24125 country: Italy lat: 45.69601 lon: 9.66721 facility: Research Site city: Genoa zip: 16132 country: Italy lat: 44.40478 lon: 8.94438 facility: Research Site city: Milano zip: 20141 country: Italy lat: 45.46427 lon: 9.18951 facility: Research Site city: Milano zip: 20162 country: Italy lat: 45.46427 lon: 9.18951 facility: Research Site city: Monza zip: 20052 country: Italy lat: 45.58005 lon: 9.27246 facility: Research Site city: Padova zip: 35128 country: Italy lat: 45.40797 lon: 11.88586 facility: Research Site city: Pavia zip: 27100 country: Italy lat: 45.19205 lon: 9.15917 facility: Research Site city: Ravenna zip: 48100 country: Italy lat: 44.41344 lon: 12.20121 facility: Research Site city: Roma zip: 00128 country: Italy lat: 41.89193 lon: 12.51133 facility: Research Site city: Rozzano zip: 20089 country: Italy lat: 45.38193 lon: 9.1559 facility: Research Site city: Kawasaki-shi zip: 216-8511 country: Japan lat: 35.52056 lon: 139.71722 facility: Research Site city: Nagoya-shi zip: 460-0001 country: Japan lat: 35.18147 lon: 136.90641 facility: Research Site city: Sagamihara-shi zip: 252-0375 country: Japan lat: 35.54899 lon: 139.26064 facility: Research Site city: Sapporo-shi zip: 003-0804 country: Japan lat: 43.06667 lon: 141.35 facility: Research Site city: Takatsuki-shi zip: 569-8686 country: Japan lat: 34.84833 lon: 135.61678 facility: Research Site city: Tokushima-shi zip: 770-8503 country: Japan lat: 34.06667 lon: 134.56667 facility: Research Site city: Utsunomiya-shi zip: 320-0834 country: Japan lat: 36.56667 lon: 139.88333 facility: Research Site city: Changwon zip: 51353 country: Korea, Republic of lat: 35.22806 lon: 128.68111 facility: Research Site city: Incheon zip: 21565 country: Korea, Republic of lat: 37.45646 lon: 126.70515 facility: Research Site city: Seongnam-si zip: 13496 country: Korea, Republic of lat: 37.43861 lon: 127.13778 facility: Research Site city: Seoul zip: 03080 country: Korea, Republic of lat: 37.566 lon: 126.9784 facility: Research Site city: Seoul zip: 03722 country: Korea, Republic of lat: 37.566 lon: 126.9784 facility: Research Site city: Suwon-si zip: 16499 country: Korea, Republic of lat: 37.29111 lon: 127.00889 facility: Research Site city: Suwon zip: 16247 country: Korea, Republic of lat: 37.29111 lon: 127.00889 facility: Research Site city: Olsztyn zip: 10-357 country: Poland lat: 53.77995 lon: 20.49416 facility: Research Site city: Poznań zip: 60-569 country: Poland lat: 52.40692 lon: 16.92993 facility: Research Site city: Warszawa zip: 01-138 country: Poland lat: 52.22977 lon: 21.01178 facility: Research Site city: Alicante zip: 03010 country: Spain lat: 38.34517 lon: -0.48149 facility: Research Site city: Barcelona zip: 08003 country: Spain lat: 41.38879 lon: 2.15899 facility: Research Site city: Barcelona zip: 08036 country: Spain lat: 41.38879 lon: 2.15899 facility: Research Site city: Jerez de la Frontera zip: 11407 country: Spain lat: 36.68645 lon: -6.13606 facility: Research Site city: Reus,Tarragona zip: 43204 country: Spain facility: Research Site city: Salamanca zip: 37007 country: Spain lat: 40.96882 lon: -5.66388 facility: Research Site city: Kaohsiung zip: 80756 country: Taiwan lat: 22.61626 lon: 120.31333 facility: Research Site city: New Taipei zip: 220 country: Taiwan lat: 25.01111 lon: 121.44583 facility: Research Site city: Taichung zip: 40447 country: Taiwan lat: 24.1469 lon: 120.6839 facility: Research Site city: Tainan zip: 704 country: Taiwan lat: 22.99083 lon: 120.21333 facility: Research Site city: Taipei zip: 10002 country: Taiwan lat: 25.04776 lon: 121.53185 facility: Research Site city: Taipei zip: 112 country: Taiwan lat: 25.04776 lon: 121.53185 facility: Research Site city: Taipei zip: TAIWAN country: Taiwan lat: 25.04776 lon: 121.53185 facility: Research Site city: Taoyuan zip: 333 country: Taiwan lat: 24.95233 lon: 121.20193 facility: Research Site city: Adapazarı zip: 54100 country: Turkey lat: 40.78056 lon: 30.40333 facility: Research Site city: Ankara zip: 06560 country: Turkey lat: 39.91987 lon: 32.85427 facility: Research Site city: Ankara zip: 6200 country: Turkey lat: 39.91987 lon: 32.85427 facility: Research Site city: Antalya zip: 07070 country: Turkey lat: 36.90812 lon: 30.69556 facility: Research Site city: Diyarbakir zip: 21280 country: Turkey lat: 37.91363 lon: 40.21721 facility: Research Site city: Istanbul zip: 34030 country: Turkey lat: 41.01384 lon: 28.94966 facility: Research Site city: Istanbul zip: 34890 country: Turkey lat: 41.01384 lon: 28.94966 facility: Research Site city: Inverness zip: IV2 3UJ country: United Kingdom lat: 57.47908 lon: -4.22398 facility: Research Site city: London zip: SE1 9RT country: United Kingdom lat: 51.50853 lon: -0.12574 facility: Research Site city: London zip: SW10 9NH country: United Kingdom lat: 51.50853 lon: -0.12574 facility: Research Site city: London zip: SW17 0QT country: United Kingdom lat: 51.50853 lon: -0.12574 facility: Research Site city: Truro zip: TR1 3LJ country: United Kingdom lat: 50.26526 lon: -5.05436 hasResults: False
<|newrecord|> nctId: NCT06357520 id: D6970C00005 briefTitle: A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants overallStatus: RECRUITING date: 2024-04-16 date: 2024-06-06 date: 2024-06-06 date: 2024-04-10 date: 2024-04-25 name: AstraZeneca class: INDUSTRY briefSummary: The main purpose of this study is to assess the effect of itraconazole on the pharmacokinetic (PK) of baxdrostat. conditions: Healthy Participants studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 14 type: ESTIMATED name: Baxdrostat name: Itraconazole measure: Area Under Plasma Concentration-Time Curve From Time Zero To Infinity (AUCinf) measure: Maximum Observed Plasma Drug Concentration (Cmax) measure: Extrapolated Area Under The Curve From Tlast to Infinity (AUCextr) measure: Area Under Plasma Concentration Curve from Time Zero to the Last Quantifiable Concentration (AUClast) measure: Apparent Total Body Clearance (CL/F) measure: Apparent Volume Of Distribution Based On The Terminal Phase (Vz/F) measure: Terminal Elimination Half-life (t1/2λz) measure: Terminal Rate Constant (λz) measure: Mean Residence Time (MRTinf) measure: Time To Reach Maximum Observed Concentration (tmax) measure: Ratio of Baxdrostat (Baxdrostat + Itraconazole) to Baxdrostat (Alone) Based on Maximum Plasma Concentration (RCmax) measure: Ratio of Baxdrostat (Baxdrostat + Itraconazole) to Baxdrostat (Alone) Based on AUClast (RAUClast) measure: Ratio of Baxdrostat (Baxdrostat + Itraconazole) to Baxdrostat (Alone) Based on AUCinf (RAUCinf) measure: Number of Participants with Adverse Events sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Research Site status: RECRUITING city: Brooklyn state: Maryland zip: 21225 country: United States lat: 39.23039 lon: -76.60219 hasResults: False
<|newrecord|> nctId: NCT06357507 id: hayam hamdy briefTitle: Molecular Characterization of Moraxella Catarrhalis From Pneumonic Children at Pediatric Assiut University Hospital acronym: Mcatarrhalis overallStatus: NOT_YET_RECRUITING date: 2024-12-01 date: 2027-12-01 date: 2027-12-20 date: 2024-04-10 date: 2024-04-16 name: Assiut University class: OTHER briefSummary: moraxella catarrhalis is responsible for respiratory tract infection in children and adults with streptococcus pneumonia and haemophilus influenza.Moraxella catarrhalis is gram negative diplococci, non-motile and non spore bearing bacteria. Until, 1995 it was considered as a non pathogenic respiratory tract flora.This bacteria is an important pathogen and a common cause of both upper and lower respiratory tract infections, pneumonia, sinusitis and conjunctivitis in infants, children and in elderly patients. In adults, M. catarrhalis also causes chronic obstructive pulmonary disease (COPD) and pneumonia. However, it is associated with a number of respiratory infections affecting both children and adults, including laryngitis, bronchitis and pneumonia . conditions: Respiratory Tract Infections studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 90 type: ESTIMATED measure: isolation of moraxella catarrhalis measure: detection of virulence genes of moraxella catarrhalis measure: detetion of antibiotic resistance sex: ALL minimumAge: 1 Month stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<|newrecord|> nctId: NCT06357494 id: Thyroid Doppler in Graves' briefTitle: Assessment of Thyroid Doppler Ultrasound in Followup of Pediatric Graves' Disease overallStatus: NOT_YET_RECRUITING date: 2024-04-05 date: 2027-04-05 date: 2028-04-05 date: 2024-04-10 date: 2024-04-10 name: Assiut University class: OTHER briefSummary: All cases of the study will be diagnosed as Graves' by History, examination, laboratory (FT3, FT4, TSH \& TRAbs), X-ray on left wrist for bone age, neck grey scale ultrasonography for thyroid gland size, shape, echotexture, vascularity and nodule characters if present with TIRAD score calculation.
Then Color flow doppler ultrasound will be done to asses thyroid volume, number of vessels per square cm and inferior thyroid artery peak systolic velocity, end diastolic velocity and resistive index. Patients then will receive carbimazole antithyroid drug at dose 0.25-0.5 mg/kg/day PO \& the dose will be titrated according to thyroid function test after 4-6 weeks.
Beta-adrenergic blockade will be added to all symptomatic cases. Regular follow up will be done every month of first 3 months of diagnosis and then every 3 months for 2 years by clinical and thyroid function test to asses response, compliance, complications, drug side effects, remission and relapses.
Doppler ultrasound will be done at 0, 12 and 24 months. conditions: Doppler Ultrasound in Follow up of Graves' Patients studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 32 type: ESTIMATED measure: To make follow up of graves disease easier and improve patients adherence to treatment and follow up plan. measure: better control of disease in our patients, less complications, less mortality and better prognosis. sex: ALL minimumAge: 1 Year maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
<|newrecord|> nctId: NCT06357481 id: SaglikBilimleriU-22-122 briefTitle: Evaluation of Postoperative Pain After Single Visit Retreatment of Symptomatic and Asymptomatic Teeth acronym: Endodontics overallStatus: COMPLETED date: 2023-01-26 date: 2023-01-30 date: 2024-01-28 date: 2024-04-10 date: 2024-04-17 name: Saglik Bilimleri Universitesi class: OTHER briefSummary: Introduction: The aim of this study comparing the post operative pain after the retreatment of asymptomatic and symptomatic teeth that during single visit treatment with rotary and reciprocal nickel titanium files.
Methods: One hundred and forty one patients scheduled for non-surgical endodontic retreatment were included for evaluation. Eighty five patients who needed endodontic retreatment were assingned to 2 groups according to semptomatic or asemptomatic teeth and 4 subgroups with rotary and resiprocal files. Endodontic filling material was removed with One Flare and MicroMega REMOVER files in the retreatment kit. Patients then recorded their postoperative pain on a VAS scale at 24h, 48h, 72h, 7 days and 14 days post-treatment. Results were analyzed using the Shapiro-Wilk, Mann-Whitney U, Kruskal-Wallis, Dunn-Bonferroni and Pearson Chi-square tests. conditions: Post-operative Pain conditions: Retreatment conditions: Symptomatic Periapical Periodontitis conditions: Endodontic Disease conditions: Asymptomatic Periapical Periodontitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Eighty patients who needed endodontic retreatment were assingned to 2 groups according to symptomatic or asymptomatic teeth and 4 subgroups with rotary and resiprocal files. primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 80 type: ACTUAL name: Endodontic Retreatment measure: Post-operative pain sex: ALL minimumAge: 18 Years maximumAge: 67 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hüseyin Gürkan Güneç city: Istanbul state: Uskudar zip: 34450 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
<|newrecord|> nctId: NCT06357468 id: UKGEB003 briefTitle: Analysis of Pain Management and Pain Perception Intrapartum and Postpartum in Women With Vaginal Births in Difference Between Physician-led and Midwife-led Birth overallStatus: RECRUITING date: 2023-01-01 date: 2024-06-30 date: 2024-12-31 date: 2024-04-10 date: 2024-04-10 name: Martin-Luther-Universität Halle-Wittenberg class: OTHER briefSummary: The aim of the analysis is to describe the differences and similarities in obstetric pain management and pain perception intrapartum and postpartum in women with vaginal births in contrast to physician-led births and midwife-led births conditions: Pain, Labor studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 400 type: ESTIMATED name: midwife-led births in low risk women in pregnancy measure: Pain perception measure: Satisfaction with pain therapy measure: Pain perception in women with perineal tear grade III sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital of Halle status: RECRUITING city: Halle state: Saxony Anhalt zip: 06120 country: Germany name: Marcus Riemer, MD role: CONTACT phone: 03455573946 email: [email protected] lat: 51.48159 lon: 11.97948 hasResults: False
<|newrecord|> nctId: NCT06357455 id: Platelet CellSaver Liver trnsp briefTitle: Platelet Count and Function After Usage of Two Different Cell Saver Devices During Liver Transplant Surgery acronym: PLFLTS overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-06-01 date: 2025-06-01 date: 2024-04-10 date: 2024-04-10 name: Eduardo Schiffer class: OTHER name: University Hospital, Geneva name: Insel Gruppe AG, University Hospital Bern briefSummary: Intraoperative cell salvage is commonly used in surgeries that carry a major hemorrhagic risk to reduce the administration of allogeneic red blood cells and thus improve the outcome for the patient. When processing the salvaged blood, however, a large part of the patient's plasma is washed out. This is a disadvantage with regard to an optimal coagulation status after these types of surgeries, especially liver transplantation.
There are currently various cell saver systems on the market. According to the manufacturers, the plasma is returned to the patient in different quantities as part of the processing procedure. Thus, it can be assumed that in addition to red blood cells, platelets (part of plasma) are re-transfused and contribute to an optimized coagulation. Unfortunately, there is a lack of studies in this regard in the liver transplant surgery population.
The investigators aim to study the performance of two different cell saver devices regarding preservation of platelet number and function. conditions: Liver Transplant conditions: Hemorrhage, Surgical studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Cell Salvage Autotransfusion: SAME™ device name: Cell Salvage Autotransfusion: Autolog™ device measure: Platelet number measure: Platelet function measure: Platelet function measure: Platelet function measure: Platelet function measure: Platelet function measure: Platelet function measure: Blood plasma albumin level measure: Blood hemoglobin level measure: Blood lactate level measure: Free hemoglobin level measure: Anti-Xa activity measure: Number of allogeneic blood products used measure: Number of coagulation concentrates used measure: Amount of autologous blood at the end of the liver transplantation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Geneva University Hospitals city: Geneva zip: 1211 country: Switzerland name: Eduardo Schiffer, MD role: CONTACT email: [email protected] name: Tony Mouawad, MD role: PRINCIPAL_INVESTIGATOR lat: 46.20222 lon: 6.14569 hasResults: False
<|newrecord|> nctId: NCT06357442 id: 23-2305 briefTitle: Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant. overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-04 date: 2024-04-10 date: 2024-04-10 name: University of Colorado, Denver class: OTHER briefSummary: The goal of this observational study is to compare endometrial stripe thickness in adolescent and young adult (AYA) patients with a uterus on estrogen replacement therapy using oral progesterone versus the etonogstrel implant for endometrial protection.
The main questions it aims to answer are:
Aim 1: Characterize the mean endometrial thickness in AYA on estrogen hormone replacement therapy before initiation of progesterone therapy
Aim 2: Characterize the mean changes and variability in endometrial thickness in AYA treated for 6 months with either the etonogestrel implant or continuous oral progesterone
Aim 3: Assess satisfaction, side effects, bleeding patterns, any progesterone modifications, and adherence in AYA treated for 6 months with either etonogestrel implant or continuous progesterone
Participants will be asked to:
* Get two pelvic ultrasounds
* Fill out two surveys
* Continue their current hormone replacement therapy
* Initiate one of two progesterone therapies (prometrium 100mg daily or Nexplanon)
Researchers will compare the change in endometrial thickness after 6 months of progesterone use to see if there is a significant difference in the mean change between the prometrium and Nexplanon groups. conditions: Primary Ovarian Insufficiency conditions: Hypogonadotropic Hypogonadism conditions: Hormone Replacement Therapy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 34 type: ESTIMATED measure: Mean change in endometrial thickness after 6 months of progesterone therapy measure: Measure the mean endometrial thickness on estrogen replacement therapy measure: Satisfaction of progesterone replacement therapy measure: Bleeding patterns on progesterone replacement therapy measure: Side effects of progesterone replacement therapy measure: Adherence to progesterone replacement therapy measure: Rate of enrollment and attrition measure: Number of patients willing to be randomized in future trial sex: FEMALE minimumAge: 12 Years maximumAge: 25 Years stdAges: CHILD stdAges: ADULT hasResults: False
<|newrecord|> nctId: NCT06357429 id: 171002100 briefTitle: Evaluation of the Effect of the LI4 Cold Application acronym: LI4 overallStatus: COMPLETED date: 2022-02-23 date: 2022-11-18 date: 2022-11-18 date: 2024-04-10 date: 2024-04-10 name: Saglik Bilimleri Universitesi class: OTHER briefSummary: It is an experimental study conducted to evaluate the effectiveness of cold application to the LI4 point of the hand to reduce/eliminate pain, nausea and anxiety in postoperative patients. The population of the study consisted of 116 individuals who underwent abdominal surgery with the open surgery method in a state hospital between February 2022 and November 2022 and were followed up in the inpatient ward. The study was completed with 80 individuals constituting the experimental group (n=40) and the control group (n=40). Patient information form, Mcgill Melzack short pain form, Visual Analog Scale, STAI - TX and Cold Application Evaluation Form were used to collect data. Patients in the experimental group underwent cold application with ice cubes for a total of 20 minutes as 2 minutes of cold application and 15 seconds of waiting 4-6 hours after the patient was admitted to the clinic after surgical intervention. Follow-up was performed before cold application, immediately after cold application, 30 minutes after the end of cold application, 1 hour and 2 hours after the end of cold application. conditions: Pain conditions: Nausea conditions: Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 80 type: ACTUAL name: Cold Application measure: Pain Level measure: Nausea Level measure: Anxiety Level measure: Sensory characteristics, intensity and impact of pain sex: FEMALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Saglik Bilimleri University city: Istanbul state: Uskudar zip: 34674 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
<|newrecord|> nctId: NCT06357416 id: CCR5573 briefTitle: The Man Van Project acronym: MV overallStatus: RECRUITING date: 2022-04-13 date: 2025-10-01 date: 2026-12-01 date: 2024-04-10 date: 2024-04-10 name: Royal Marsden NHS Foundation Trust class: OTHER name: RM Partners West London Cancer Alliance name: Institute of Cancer Research, United Kingdom name: Imperial College London briefSummary: National Health Service (NHS) England has commissioned The Royal Marsden Hospital NHS Foundation Trust to run a novel mobile clinical outreach service called 'Man Van' with the aim of enabling male patients' easy access to care at the site of their work and in their communities. The initial focus of this new standard of care clinic is to access workplaces with large manual workforces where large scale working from home is not possible. These will include logistics firms and bus companies. These companies employ large numbers of black and minority ethnic men who also have poorer outcomes with a range of other diseases, including Coronavirus disease (COVID)-19. The novel clinical service will collaborate with Unite (and other unions) as well as employers in order to reach our target groups effectively. There is also the opportunity to target higher risk groups e.g. Afro Caribbean communities whose rates of prostate cancer are 1 in 41 as well as occupational higher risk categories. The Man Van has the potential to swing the balance of evidence in favour of Prostate-Specific Antigen (PSA) screening, with a targeted screening program directed at high-risk groups including ethnic minorities and manual workers. Reasons for poorer outcomes amongst these groups are multi-factorial and complex. Levels of education are often a factor which can impact the understanding of the disease and how to seek assistance. Distrust of medical organisations has also been cited as a factor.
The aim of the Man Van mobile outreach service is to enable men access to a specific men's health service - focusing on general health and wellbeing (including BMI assessment, blood pressure, blood sugar/diabetes checks etc) and a prostate check for those who raise concerns. This will include a PSA test where relevant. This will be the core data gathered from the project.
Patients will receive PSA results in the 'Man Van' by a clinical nurse specialist with patients with raised PSA levels being referred into the standard rapid referral cancer pathways. Similar considerations will apply to men with haematuria detected on dip stick testing or who present with a testicular mass or penile lesion (both rare but important).
The clinical data generated from each routine health screening appointment will be analysed to determine the effectiveness of the Man Van mobile outreach model in identifying prostate and other male cancers and other co-morbidities much earlier than if patients had waited to present to their General Practitioner (GP) or other healthcare provider.
Patients who receive an early diagnosis of clinically significant prostate cancer will have access to early curative treatments, which are typically less invasive and shorter in timescales. Similar interventions have shown large scale success in particular with breast and cervical cancer.
The NHS sees many patients accessing cancer care at a late stage. Reducing this trend is a key objective of the NHS Long Term Plan. The COVID-19 pandemic has further exacerbated health inequalities and mobile clinics can potentially be a model for alleviating this. To enable patients access to medical treatment earlier there is a need to make the 'seeking advice on men's health and prostate issues' less daunting, more normal and easily accessible. The 'Man Van' has the ability to do just that and it is anticipated that the findings of this research, using the data generated from each patient's routine health screening, will demonstrate that a mobile outreach model is more effective in identifying cancers at an earlier stage than 'traditional' diagnostic pathways.
We also hope to evaluate the Man Van with a qualitative study looking at the patient perspectives from those who utilise the Man Van.
The reasons for high risk in prostate cancer are heavily linked to genetics. This is an issue as there is less recruitment of high risk groups to studies. We hope to gather genetic data from a higher proportion of genetically susceptible men via the Man Van, which can be used in future to further genetic knowledge of prostate cancer. conditions: Prostate Cancer conditions: Urologic Cancer conditions: Urologic Diseases conditions: Bladder Cancer conditions: Diabetes conditions: Hypertension conditions: Mental Health Issue conditions: Alcoholism conditions: Smoking conditions: Renal Cancer conditions: Testis Cancer studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 4000 type: ESTIMATED name: MV-POCT Sub-study name: Main Man Van Group Sub-study name: MV-QualQ Sub-study name: MV-PRS Sub-study name: MV-DNA and MV-UctDNA Sub-study name: Man Van patients measure: Cancer detection rates measure: Detection rates of other diseases sex: MALE minimumAge: 45 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Royal Marsden Hospital NHS Foundation Trust status: RECRUITING city: London zip: SW3 6JJ country: United Kingdom name: Ann Gandolfi role: CONTACT phone: 02086613903 email: [email protected] lat: 51.50853 lon: -0.12574 hasResults: False
<|newrecord|> nctId: NCT06357403 id: AntiXa-ICU 1881/2023 briefTitle: Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients acronym: AntiXa-ICU overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-05 date: 2026-08 date: 2024-04-10 date: 2024-04-10 name: Medical University of Vienna class: OTHER briefSummary: The goal of this observational study is to analyse the association between anti-factor Xa activity (antiXa) and the occurence of venous thromboembolism (VTE; either deep vein thrombosis and/or pulmonary embolism) in critically ill patients who are admitted to an intensive care unit. The main questions it aims to answer are:
* What is the association between antiXa and VTE?
* What is the association between antiXa and symptomatic, respectively incidental, VTE?
* How is pharmacological anticoagulation with enoxaparin related to measured antiXa?
* What is the association between antiXa and bleeding complications.
* What is the incidence of venous thromboembolism in patients treated at an intensive care unit?
* How is the occurence of VTE related to patient-centred outcomes such as mortality, quality of life, length of stay and days outside of the intensive care unit/hospital. conditions: Thrombosis conditions: Pulmonary Embolism conditions: Enoxaparin studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1300 type: ESTIMATED name: Anti-factor Xa activity calibrated for enoxaparin measure: Number of patients with new-onset venous thromboembolism measure: Number of patients with new-onset upper extremity deep vein thrombosis measure: Number of patients with new-onset lower extremity deep vein thrombosis measure: Number of patients with new-onset central vein thrombosis measure: Number of patients with new-onset symptomatic upper extremity deep vein thrombosis measure: Number of patients with new-onset symptomatic lower extremity deep vein thrombosis measure: Number of patients with new-onset incidental upper extremity deep vein thrombosis measure: Number of patients with new-onset incidental lower extremity deep vein thrombosis measure: Number of patients with new-onset pulmonary embolism measure: Number of patients with new-onset symptomatic pulmonary embolism measure: Number of patients with new-onset incidental pulmonary embolism measure: Number of patients with venous thromboembolism measure: Number of patients with deep vein thrombosis measure: Number of patients with pulmonary embolism measure: Number of patients with new-onset venous thromboembolism measure: Number of days with any bleeding measure: Number of days with major and/or fatal bleeding measure: Number of red blood cell concentrates administered measure: Number of days on which either procoagulant medication, platelet transfusion or fresh frozen plasma was administered measure: Length of stay in the intensive care unit measure: Length of stay in the hospital measure: Death measure: Days alive and out of the intensive care unit measure: Days alive and out of the hospital measure: European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) index value measure: European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) visual analogue scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<|newrecord|> nctId: NCT06357390 id: 202106174RINB briefTitle: Physiologic and Clinical Effect of High-flow Oxygen Therapy in Tracheostomized Patients With Prolonged Mechanical Ventilation Undergoing Weaning Trials overallStatus: COMPLETED date: 2021-10-07 date: 2022-07-25 date: 2024-02-15 date: 2024-04-10 date: 2024-04-10 name: National Taiwan University Hospital class: OTHER briefSummary: This study is aimed at patients who have been admitted to the respiratory care center of this hospital who meet the PMV conditions (defined as continuous use of the ventilator for at least ten days) who are about to receive the ventilator out of training. After obtaining the explanatory consent, they will undergo continuous complete Before and after spontaneous breathing training, collect various relevant physiological data of lung volume and ventilation perfusion distribution, and analyze and predict the correlation of ventilator detachment. conditions: High Flow Oxygen Therapy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 10 type: ACTUAL measure: ventilation perfusion distribution measurement sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Taiwan University Hospital city: Taipei country: Taiwan lat: 25.04776 lon: 121.53185 hasResults: False
<|newrecord|> nctId: NCT06357377 id: NEO100-03 briefTitle: A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-10-31 date: 2024-10-31 date: 2024-04-10 date: 2024-04-10 name: Neonc Technologies, Inc. class: INDUSTRY briefSummary: This is an open label, Phase 1b safety, dose-finding, brain tumor delivery, and pharmacokinetics study of intranasal NEO100 in patients with pediatric-type diffuse high grade gliomas. Patients will receive IN NEO100 that will follow a dose titration design, followed by a standard dose escalation design to establish safety. Brain tumor delivery of NEO100 will be confirmed in each disease sub-type by surgical resection/needle biopsy only if clinically indicated and scheduled for clinical purposes and testing with residual tissue for NEO100 and the major metabolite of NEO100 (Perillic Acid). conditions: Pediatric Tumor of CNS conditions: Pediatric Tumor of Brain conditions: Diffuse Midline Glioma, H3 K27M-Mutant conditions: Pediatric Tumor of Brain Stem conditions: Pineocytoma conditions: Choroid Plexus Carcinoma, Childhood conditions: Spinal Cord Tumor conditions: High Grade Glioma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: NEO100 measure: Nature and severity of adverse events measure: Identify the maximum tolerated dose (MTD) of NEO100 measure: Determine the recommended Phase 2 dose (RP2D) of NEO100 measure: Measurement of NEO100 and its metabolite perillic acid in brain tumor tissue measure: Blood brain barrier penetration measure: Characterize the pharmacokinetics (PK) of NEO100 as measured by Peak Plasma Concentration measure: Characterize the pharmacokinetics (PK) of NEO100 as measured by the Time to Peak Plasma Concentration measure: Characterize the pharmacokinetics (PK) of NEO100 as measured by Area Under the Curve measure: To assess efficacy of NEO100 based on objective response rate (ORR). measure: To assess efficacy of NEO100 based on progression free survival (PFS). measure: To assess efficacy of NEO100 based on overall survival (OS). sex: ALL minimumAge: 5 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
<|newrecord|> nctId: NCT06357364 id: CBT_Procrastination_Neuro briefTitle: Neural Changes Following Cognitive Behavior Therapy for Procrastination overallStatus: RECRUITING date: 2024-04-08 date: 2026-01-15 date: 2026-01-15 date: 2024-04-10 date: 2024-04-10 name: Nencki Institute of Experimental Biology of the Polish Academy of Sciences class: OTHER_GOV name: SWPS University of Social Sciences and Humanities name: Institute of Psychology, Polish Academy of Sciences briefSummary: The aim of this study is to compare the efficacy of and the neural changes following two cognitive behavior therapy (CBT) protocols for procrastination with a wait-list control group. The interventions will be delivered online in group settings. Both protocols include identical psychoeducation and cognitive modules aiming at identification and modification of dysfunctional automatic thoughts related to procrastination but will differ in the behavioral modules. The behavioral module in the first protocol is focused on timely beginning and realistic planning. The second protocol implements working time restriction. The wait-list control group will receive one of the CBT protocols after a waiting period that will last as long as the CBT intervention and the assessments performed directly after treatment. It is assumed that the interventions will be superior to the wait-list control. Primary (procrastination) and secondary (depression and anxiety) measures will be collected prior to and after the interventions (or waiting period in the wait-list group) and after 6 months in the two active condition groups. Additionally, neuroimaging measurements will be conducted before and after the interventions (or waiting period in the wait-list group). Approximately half of the participants will undergo functional Magnetic Resonance Imaging (fMRI), and another half will undergo electroencephalography (EEG). Both methods are aimed at exploring neural correlates of the expected improvements in participants' self-regulation abilities. conditions: Procrastination studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: A researcher not having direct contact with participants will create a script generating random sequence using a computer random sequence generator (Matlab). Randomization will take place at an individual level, stratified by age, gender and procrastination severity (block randomization). Participants will be randomized into three groups with an allocation ratio of 1:1:1.